Enter your keywords
HOME
About Us
NEWSLETTER
To search AlzGene, use the "Keyword" search on the
AlzGene search page
.
NEWS
All News
Conference Coverage
Series
WEBINARS
All Webinars
Databases
AlzBiomarker
AlzPedia
AlzRisk
Antibodies
Genetics
AlzGene
HEX
Mutations
Protocols
Research Models
Therapeutics
PAPERS
All Papers
Papers of the Week
Milestone
Alzforum Recommends
PROFESSIONAL RESOURCES
Conference Calendar
Grants
Jobs
Member Directory
ABOUT AD
AD Overview
Early-Onset Familial
The HBO Alzheimer's Project
Supported Browsers
MY ALZFORUM
My AlzForum Home
View Library
View Notifications
Set Notifications
Edit Profile
AlzGene - Gene overview of all published AD-association studies for MAPT/STH
Gene:
MAPT/STH
(TAU; MTBT2; FTDP-17; FLJ31424; MSTD; PPND; DDPAC; MAPTL; MTBT1; STH/MAPT)
View on ALSGene
View on MSGene
View on PDGene
View on SZGene
Protein:
microtubule-associated protein tau/saitohin
(microtubule-associated protein tau; saitohin)
Chromosome:
17
(View:
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
X
Y
MT
)
Status:
Updated 18 April 2011
; Because of the complete correlation between genetic markers in MAPT and STH, these two loci have been combined for display in this database
1. Case-Control Studies (by ethnic group)
AD Cases
Normal Controls
Study
Population
Source
# Polys
# Subjects
(% women)
DX
Onset Age
(range)
Age
(range)
# Subjects
(% women)
Age
(range)
Result
Comment
Caucasian
Abraham, 2009
UK
CL
6
(detail)
1082
(71%)
C
75.8 + 6.7
(60-95)
-
1239
(62%)
76.5 + 6.3
(-)
Trend
Baker, 2000
Finland
PO
1
(detail)
110
(-)
M
-
-
174
(-)
-
Negative
Bullido, 2000
Spain
CL
1
(detail)
167
(-)
M
69.1 + 5.1
(53-79)
-
194
(-)
68.2 + 7.4
(-)
Positive
Clark, 2003
USA
CL
1
(detail)
15
(-)
C
-
-
129
(-)
-
Negative
Combarros, 2003
Spain
CL
1
(detail)
315
(70%)
C
71.9 + 8.8
(48-95)
75.6 + 9
(50-98)
307
(72%)
80.5 + 7.7
(63-100)
Positive
Conrad, 1997
Unknown
1
(detail)
173
(-)
U
-
-
61
(-)
-
Negative
Conrad, 2004
Germany
CL
1
(detail)
155
(-)
N
-
80.9 + 6.9
(-)
41
(-)
76.1 + 5.6
(-)
Negative
Cook, 2002
UK
CL
1
(detail)
203
(66%)
N
-
81.4 + 7.8
(-)
309
(59%)
82.1 + 3.8
(-)
Negative
Cousin, 2009
France
CL
7
(detail)
428
(-)
C
64.9 + 9.9
(-)
-
475
(-)
66.2 + 10.8
(-)
Trend
Ezquerra, 1999
Spain
1
(detail)
74
(51%)
C
65.2 + 10.5
(-)
-
195
(51%)
61.4 + 13.9
(-)
Negative
Feulner, 2009
Germany
CL
20
(detail)
491
(57%)
C
-
72.2
(-)
479
(46%)
39.5
(-)
Positive
Garcia, 2009
Overlaps with
Combarros, 2003
CL
1
(detail)
285
(63%)
C
-
75.9 + 8.7
(50-97)
382
(67%)
81 + 7.7
(51-100)
n.a.
Giedraitis, 2009
Sweden (ULSAM)
CL
1
(detail)
86
(0%)
C
80.2
(72-85)
-
404
(0%)
81.8
(80-84)
Negative
Johansson, 2005
Sweden
1
(detail)
398
(58%)
M
73 + 7.7
(-)
77 + 7.1
(-)
186
(56%)
72 + 9.2
(-)
Negative
Kaivorinne, 2008
Finland
CL
1
(detail)
122
(55%)
C
-
58.2
(38-64)
198
(-)
40.6
(19-64)
Positive
Kauwe, 2008
USA
CL
1
(detail)
361
(-)
C
-
-
358
(-)
-
Positive
Kwok, 2008
UK
CO
3
(detail)
604
(68%)
C
-
82 + 6.4
(-)
589
(69%)
77 + 6.5
(-)
Positive
Kwok, 2008
Australia
PO
3
(detail)
129
(-)
C
-
-
171
(-)
-
Positive
Kwon, 2000
USA
CL
1
(detail)
266
(50%)
C
70 + 9.1
(-)
-
278
(59%)
74.5 + 9
(-)
Negative
Laws, 2006
Germany
CL
6
(detail)
433
(59%)
C
69.3 + 9.4
(-)
72.4 + 9.5
(-)
279
(57%)
67.2 + 11.6
(-)
Positive
Li, 2008
Canada
CL
4
(detail)
753
(58%)
C
71.9 + 8.5
(-)
77.8 + 8.6
(-)
736
(64%)
73.4 + 7.9
(-)
Trend
Lilius, 1999
Sweden (I)
CL
7
(detail)
136
(-)
M
65 + 9
(-)
-
62
(-)
73 + 12
(-)
Negative
Lilius, 1999
Sweden (II)
PO
7
(detail)
94
(-)
C
80 + 5
(-)
-
176
(-)
88 + 4
(-)
Negative
Mateo, 2006
Overlaps with
Combarros, 2003
CL
1
(detail)
333
(67%)
C
72.1 + 8.6
(48-95)
75.7 + 9
(50-98)
307
(70%)
80.4 + 7.8
(63-100)
n.a.
Mateo, 2008
Spain
CL
1
(detail)
293
(65%)
C
72.1 + 8.2
(48-93)
-
396
(67%)
81 + 7.6
(51-100)
Negative
Mukherjee, 2007
USA (WashU)
CL
6
(detail)
361
(-)
C
-
-
358
(-)
-
Negative
Myers, 2005
USA
6
(detail)
181
(55%)
N
-
81
(66-97)
131
(51%)
81
(65-99)
Positive
Myers, 2005
UK
6
(detail)
179
(66%)
N
-
81
(65-96)
121
(51%)
78
(65-100)
Positive
Myers, 2006
Overlaps with
Schjeide, 2009
CL
6
(detail)
296
(55%)
N
-
83
(65-102)
128
(44%)
80
(65-102)
Positive
Oliveria, 2003
USA
CL
1
(detail)
903
(67%)
M
-
-
320
(54%)
-
Negative
Peplonska, 2003
Poland
CL
1
(detail)
100
(64%)
C
71.5 + 4.2
(-)
76.4 + 4.1
(-)
100
(79%)
71.2 + 5.9
(-)
Negative
Randall, 2009
USA
CL
1
(detail)
181
(71%)
C
-
-
119
(52%)
-
Positive
Reiman, 2007
USA, Netherlands
CL
3
(detail)
861
(-)
M
-
74.9 + 6.6
(-)
550
(-)
77.4 + 7.3
(-)
Negative
Roks, 1999
Netherlands
PO
2
(detail)
101
(-)
C
57 + 5
(-)
63 + 4.9
(-)
117
(-)
61 + 3.3
(-)
Negative
Russ, 2001
UK
CO
1
(detail)
200
(76%)
C
77.5 + 7.3
(-)
-
189
(-)
80.1 + 4
(-)
Negative
Seripa, 2004
USA
CL
1
(detail)
117
(55%)
N
71.6 + 8.8
(-)
80.9 + 7.9
(-)
99
(54%)
83.7 + 8.2
(-)
Negative
Seripa, 2004
Italy
CL
1
(detail)
130
(58%)
C
65.9 + 7.2
(-)
69.8 + 7.3
(-)
105
(46%)
62.4 + 10.5
(-)
Negative
Streffer, 2003
Switzerland
CL
1
(detail)
91
(-)
C
-
-
92
(-)
-
Negative
Streffer, 2003
Greece
CL
1
(detail)
134
(-)
C
-
-
52
(-)
-
Negative
Vazquez-Higuera, 2009
Overlaps with
Mateo, 2008
CL
1
(detail)
246
(65%)
C
72.9 + 7.1
(60-93)
76.6 + 7.3
(62-97)
237
(69%)
81.2 + 7.7
(63-100)
n.a.
Verpillat, 2002
Overlaps with
Cousin, 2009
CL
1
(detail)
499
(62%)
-
63.8 + 9.7
(41-90)
-
402
(52%)
66.6 + 10.2
(-)
n.a.
Webster, 2010
Overlaps with
Reiman, 2007
CL
1
(detail)
861
(-)
M
-
82.8 + 7.7
(-)
550
(-)
79.7 + 6.3
(-)
Negative
Zuo, 2006
USA
CL
1
(detail)
369
(61%)
C
69.3 + 8.3
(45-87)
73.6 + 8.4
(52-93)
289
(55%)
40.8 + 8.3
(18-88)
Negative
African Descent
Clark, 2003
USA
CL
1
(detail)
65
(-)
C
-
-
118
(-)
-
Negative
Asian
Kwok, 2008
China
CL
3
(detail)
179
(93%)
C
-
84.3 + 6.2
(-)
188
(73%)
73.8 + 7.1
(-)
Positive
Lin, 2008
China
CL
1
(detail)
280
(75%)
C
75.8 + 9.7
(-)
79.7 + 9.3
(-)
220
(72%)
78.5 + 8.9
(-)
Negative
Sun, 2008
China
CL
1
(detail)
252
(54%)
C
60.5 + 5.8
(-)
68.3 + 7.3
(-)
197
(53%)
69.2 + 8
(-)
Positive
Tanahashi, 2004
Japan
CL
2
(detail)
874
(65%)
C
70 + 8.8
(42-91)
-
678
(60%)
67 + 10.1
(33-91)
Positive
Wang, 2008
China
CL
1
(detail)
207
(52%)
C
-
77.6 + 6.4
(65-97)
222
(39%)
72.3 + 5.3
(65-77)
n.a.
Hispanic
Clark, 2003
USA
CL
1
(detail)
120
(-)
C
-
-
211
(-)
-
Negative
Forero, 2005
Colombia
CL
1
(detail)
106
(71%)
C
68.8 + 8.7
(-)
73.3 + 8.8
(-)
97
(-)
72.2 + 8.7
(-)
Negative
Other/Mixed
Baker, 2000
USA
1
(detail)
546
(-)
M
-
-
419
(-)
-
Negative
Conrad, 2002
USA
CL
1
(detail)
51
(-)
N
-
80.5
(56-98)
30
(-)
78.8
(55-97)
Positive
Crawford, 1999
USA
CL,CO
2
(detail)
265
(47%)
C
-
73.2 + 6.3
(-)
142
(60%)
75.2 + 7.3
(-)
Negative
Contact us
if you are an author of an association study regarding this gene and do not find your study in this table or find errors in the representation of your study details.
2. Family-Based Studies (by ethnic group)
Affecteds
Unaffecteds
Study
Population
# Polys
# Families
# Subjects
(% women)
DX
Onset Age
(range)
Age
(range)
# Subjects
(% women)
Age
(range)
Result
Comment
Other/Mixed
Oliveria, 2003
USA
1
(detail)
690
1499
(-)
M
-
-
320
(-)
-
Negative
Schjeide, 2009
USA (CAG)
1
(detail)
217
222
(59%)
M
69.2 + 9
(50-89)
-
267
(63%)
72.9 + 8.8
(49-92)
Positive
Schjeide, 2009
USA (NCRAD)
1
(detail)
340
741
(74%)
M
71.3 + 7.6
(50-98)
-
300
(55%)
71 + 8.4
(39-93)
Negative
Schjeide, 2009
USA (NIA)
1
(detail)
351
803
(64%)
M
74.1 + 7.1
(52-98)
-
290
(59%)
73.3 + 9.5
(36-94)
Negative
Schjeide, 2009
Overlaps with
Oliveria, 2003
1
(detail)
436
995
(74%)
M
72.4 + 7.7
(50-97)
-
411
(58%)
70 + 10.7
(31-93)
n.a.
Contact us
if you are an author of an association study regarding this gene and do not find your study in this table or find errors in the representation of your study details.
Source:
Source of case population -> “CL” (clinic-based), “PO” (population-based), or “CO” (community-based).
# Polys:
Number of polymorphisms tested per gene and per sample.
Onset Age and Age:
Mean or median age at onset or examination, respectively.
DX:
Criteria used to determine AD diagnosis -> "C" (clinical AD diagnosis), "N" (neuropathological AD diagnosis), "M" (mixed, i.e. AD sample contains both clinical and neuropathological cases), "U" (unknown).
Result:
Overall conclusion reached by authors of the original publication (“positive” usually indicates significant (P<0.05) association in at least one of the performed analyses, and “negative” indicates no evidence for significant association, while “trend” indicates results in between); results obtained in duplicate or largely overlapping samples are listed as "n.a.".
(-)
: Either no data provided or in case of overlap, data included in original study.
AlzGene Recent Updates
APOE
PICALM
MS4A6A
MS4A4A
MS4A4E
EPHA1
CR1
CLU
CD33
CD2AP
BIN1
ABCA7
ARID5B
CELF2
APOC4
BCAM
CLPTM1
PVRL2
LOC3884...
TNK1
MYH13
TOMM40
PCK1
SORL1
LMNA
PGBD1
UBD
GWA_7p1...
GAB2
GOLM1
GWA_15q...
GWA_9p2...
MTHFD1L
LRAT
FAM113B
PCDH11X
GWA_14q...
ATXN1
ADAM10
CD36
DPYS
TGM4
HMMR
LAMB1
PPP3CB
ADORA2B
MTP18
ESR1
CYP19A1
LIPA
CH25H
IL1RN
LPA
MTR
FAS
CHAT
CHRNA2
CHRNA6
CHRNA7
HTR2A
PIN1
NTRK2
SERPINA...
DLST
MAPT/ST...
APOC1
LRRTM3
REN
TNFRSF1...
PIK3R1
FYN
PPP1R3A
NDUFA8
MAPK8IP...
GRIN2B
TNFRSF1...
NDUFA6
PTGS2
HFE
ABCA1
LRP8
PPARG
APBB2
LDLR
IL10
BDNF
PPARA
SOAT1
NOS3
CHRNB2
CETP
MARCH5
ACE
PON1
PON2
CDK5
CTSD
VR22
LRP1
IL6
BACE1
BACE2
PSEN2
PLAU
GSTO1
GSTO2
PRSS11
IDE
CST3
PRNP
NCSTN
TF
MME
PSEN1
TCF7L2
DYRK1A
SORCS2
SORCS3
F11R
TUBB
GRN
NEDD9
ARMS2
SMAD3
VCP
WWC1
DNM2
EBF3
EIF2AK2
SEC24C
SGPL1
ABCG1
LSS
ABCG4
CYP39A1
NCAPD2
GAPDHS
ACTA2
KCNMA1
MYST4
SCD
ANK3
GOT1
SORCS1
TAP2
ENTPD7
DNMBP
CXCL10
VPS26A
C12orf4...
CCNT1
DAPK1
POMT1
IREB2
HMGCR
IGF1R
ABCB1
DSC1
NQO1
HMOX1
LIPC
HMGCS1
RFTN1
APOA1BP
FDPS
HMGCS2
PRKAB2
ADAM12
DHCR24
SOS2
ABCC9
GRB14
HK1
IRS1
NEUROD1
PDE3B
PPARGC1...
PPP1CC
SLC2A2
HECTD2
PITRM1
TARDBP
CDKN2A
IGF1
CSK
CBLC
CARD8
HMOX2
TRPC4AP
GSTZ1
NUMB
POMT2
TMEM63C
THRA
TACR2
OLIG2
TTR
TNMD
EFNA5
MAGI2
CAND1
PPIL2
CDKN2BA...
PTPLA
ACAT2
CHRNB4
DGKB
GWA_10q...
GWA_18q...
GWA_3q2...
HPCAL1
EXOC3L2
GWA_3p2...
ZNF292
PATHWAY...
PATHWAY...
PATHWAY...
TP63
TMEM132...
RGS6
NXPH1
NCAM2
GLOD4
EPHA4
EPC2
CCDC134
ATP6V0A...
ARL5B
AGPAT1
AlzGene Top Results
Top Results Details
1.
APOE_e2/3/4
2.
BIN1
3.
CLU
4.
ABCA7
5.
CR1
6.
PICALM
7.
MS4A6A
8.
CD33
9.
MS4A4E
10.
CD2AP
AlzGene Stats
Studies: 1395
Genes: 695
Polymorphisms: 2973
Meta-analyses: 320
Proud supporter of the AlzGene database.
The PDGene database
is supported by a grant from
The Michael J. Fox Foundation
in partnership with the
Alzheimer Research Forum
.
NCRAD
The National Cell Repository for Alzheimer Disease seeks to recruit 1,000 families with two or more living brothers or sisters who have been diagnosed with late onset Alzheimer’s disease.
ALSGene
AlzGene
MSGene
PDGene
SZGene
An up-to-date collection of all published genetic association studies.